Cargando…
Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes
Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039355/ https://www.ncbi.nlm.nih.gov/pubmed/35493474 http://dx.doi.org/10.3389/fimmu.2022.853561 |
_version_ | 1784694109374513152 |
---|---|
author | Del Barba, Paolo Del Tedesco, Federica Frontino, Giulio Guarneri, Maria Pia Bonfanti, Riccardo Barera, Graziano |
author_facet | Del Barba, Paolo Del Tedesco, Federica Frontino, Giulio Guarneri, Maria Pia Bonfanti, Riccardo Barera, Graziano |
author_sort | Del Barba, Paolo |
collection | PubMed |
description | Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE) may be recommended as third-line therapy in children aged over 12 years. Few reports have suggested that glucose homeostasis is impaired in some type 2 diabetic patients receiving omalizumab, and even in non-diabetic patients, fasting blood glucose and HOMA-IR values appeared to be significantly increased. We report the case of a 13-year-old girl with diabetes mellitus type 1 and chronic spontaneous urticaria (CSU) refractory to standard recommended therapy that we treated with omalizumab at a standard recommended dose of 300 mg every 4 weeks. We observed a rapid and complete remission of CSU after treatment with this humanized monoclonal antibody without detrimental effects on the patient’s glucose control especially in terms of HbA1c (glycated hemoglobin), time in glycemic range (TIR), and daily insulin needs. |
format | Online Article Text |
id | pubmed-9039355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90393552022-04-27 Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes Del Barba, Paolo Del Tedesco, Federica Frontino, Giulio Guarneri, Maria Pia Bonfanti, Riccardo Barera, Graziano Front Immunol Immunology Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE) may be recommended as third-line therapy in children aged over 12 years. Few reports have suggested that glucose homeostasis is impaired in some type 2 diabetic patients receiving omalizumab, and even in non-diabetic patients, fasting blood glucose and HOMA-IR values appeared to be significantly increased. We report the case of a 13-year-old girl with diabetes mellitus type 1 and chronic spontaneous urticaria (CSU) refractory to standard recommended therapy that we treated with omalizumab at a standard recommended dose of 300 mg every 4 weeks. We observed a rapid and complete remission of CSU after treatment with this humanized monoclonal antibody without detrimental effects on the patient’s glucose control especially in terms of HbA1c (glycated hemoglobin), time in glycemic range (TIR), and daily insulin needs. Frontiers Media S.A. 2022-04-12 /pmc/articles/PMC9039355/ /pubmed/35493474 http://dx.doi.org/10.3389/fimmu.2022.853561 Text en Copyright © 2022 Del Barba, Del Tedesco, Frontino, Guarneri, Bonfanti and Barera https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Del Barba, Paolo Del Tedesco, Federica Frontino, Giulio Guarneri, Maria Pia Bonfanti, Riccardo Barera, Graziano Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
title | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
title_full | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
title_fullStr | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
title_full_unstemmed | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
title_short | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
title_sort | case report: safety and efficacy of omalizumab in a 13-year-old patient with chronic spontaneous urticaria and type 1 diabetes |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039355/ https://www.ncbi.nlm.nih.gov/pubmed/35493474 http://dx.doi.org/10.3389/fimmu.2022.853561 |
work_keys_str_mv | AT delbarbapaolo casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT deltedescofederica casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT frontinogiulio casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT guarnerimariapia casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT bonfantiriccardo casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT bareragraziano casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes |